Ocular Therapeutix, Inc. (NASDAQ:OCUL)‘s stock had its “neutral” rating reaffirmed by equities research analysts at BTIG Research in a note issued to investors on Monday.
Several other equities analysts have also issued reports on OCUL. ValuEngine lowered Ocular Therapeutix from a “hold” rating to a “sell” rating in a research report on Tuesday, July 11th. Cantor Fitzgerald set a $35.00 price objective on Ocular Therapeutix and gave the company a “buy” rating in a research report on Monday, July 10th. Morgan Stanley reiterated an “equal weight” rating and issued a $8.00 price objective (down from $16.00) on shares of Ocular Therapeutix in a research report on Friday. Finally, Zacks Investment Research lowered Ocular Therapeutix from a “buy” rating to a “hold” rating in a research report on Tuesday, May 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and four have assigned a buy rating to the stock. The stock currently has an average rating of “Hold” and an average target price of $21.55.
Shares of Ocular Therapeutix (NASDAQ:OCUL) opened at 6.33 on Monday. The stock has a 50 day moving average of $10.44 and a 200-day moving average of $8.94. The stock’s market capitalization is $183.75 million. Ocular Therapeutix has a 52-week low of $4.04 and a 52-week high of $11.91.
Ocular Therapeutix (NASDAQ:OCUL) last issued its quarterly earnings data on Friday, May 5th. The biopharmaceutical company reported ($0.58) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.48) by $0.10. Ocular Therapeutix had a negative net margin of 2,620.06% and a negative return on equity of 80.26%. The business had revenue of $0.48 million during the quarter, compared to analyst estimates of $0.51 million. During the same quarter in the prior year, the firm posted ($0.35) earnings per share. On average, equities research analysts predict that Ocular Therapeutix will post ($2.25) EPS for the current fiscal year.
COPYRIGHT VIOLATION WARNING: This article was posted by Ticker Report and is the property of of Ticker Report. If you are reading this article on another domain, it was stolen and republished in violation of U.S. & international copyright and trademark laws. The original version of this article can be accessed at https://www.tickerreport.com/banking-finance/2722276/ocular-therapeutix-inc-nasdaqocul-stock-rating-reaffirmed-by-btig-research.html.
A number of large investors have recently added to or reduced their stakes in the stock. Parametric Portfolio Associates LLC boosted its stake in Ocular Therapeutix by 1.3% in the first quarter. Parametric Portfolio Associates LLC now owns 30,582 shares of the biopharmaceutical company’s stock valued at $284,000 after buying an additional 401 shares during the last quarter. American International Group Inc. boosted its stake in Ocular Therapeutix by 8.2% in the first quarter. American International Group Inc. now owns 11,138 shares of the biopharmaceutical company’s stock valued at $103,000 after buying an additional 844 shares during the last quarter. Berson & Corrado Investment Advisors LLC boosted its stake in Ocular Therapeutix by 5.8% in the first quarter. Berson & Corrado Investment Advisors LLC now owns 32,805 shares of the biopharmaceutical company’s stock valued at $304,000 after buying an additional 1,785 shares during the last quarter. Highbridge Capital Management LLC purchased a new stake in Ocular Therapeutix during the first quarter valued at approximately $107,000. Finally, Janney Montgomery Scott LLC purchased a new stake in Ocular Therapeutix during the first quarter valued at approximately $110,000. Hedge funds and other institutional investors own 65.25% of the company’s stock.
Ocular Therapeutix Company Profile
Ocular Therapeutix, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye.
Receive News & Ratings for Ocular Therapeutix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ocular Therapeutix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.